Skip to main content

Table 2 Intervention outcome

From: Is adherence therapy an effective adjunct treatment for patients with schizophrenia spectrum disorders? A systematic review and meta-analysis

  

Intervention group

Control group

Effect size

Study

Outcome measures

n

Baseline mean (SD)

Follow-up mean (SD)

n

Baseline mean (SD)

Follow-up mean (SD)

SMD (95 % CI)

Anderson et al. (2010) [19]

PETiT

10

40.10 (9.24)

37.30 (8.87)

13

40.10 (10.29)

41.61 (8.63)

−0.48 (−1.31, 0.36)

 

PANSS

10

74.60 (13.79)

64.40 (30.54)

13

81.2 (17.66)

72.53 (19.20)

−0.32 (−1.15, 0.51)

Chien et al. (2015) [18]

PANSS

54

80.19 (11.10)

68.12 (14.81)

56

81.13 (12.01)

83.45 (14.13)

−1.05 (−1.45, −0.65)

 

ITAQ

54

9.12 (6.14)

13.88 (6.80)

56

9.33 (3.31)

9.79 (6.21)

0.62 (0.24, 1.01)

 

ARS

54

1.48 (0.98)

3.08 (1.24)

56

1.39 (1.01)

1.48 (1.01)

1.41 (0.99, 1.83)

Gray et al. (2006) [5]

SAI-C

173

5.04 (1.39)

5.22 (1.57)

189

4.73 (1.63)

5.03 (1.55)

0.12 (−0.08, 0.33)

 

MAQ

172

2.98 (1.24)

3.20 (1.07)

194

2.97 (1.20)

3.33 (1.02)

−0.12 (−0.33, 0.08)

 

BPRS

175

45.96 (13.23)

38.11 (11.33)

196

44.31 (12.79)

37.34 (9.79)

0.07 (−0.13, 0.28)

Maneesakorn et al. (2007) [21]

DAI-30

14

19.19 (6.96)

21.63 (5.91)

14

15.38 (9.82)

13.50 (7.58)

1.16 (0.35, 1.97)

 

SWAM

14

116.81 (26.83)

126.50 (18.40)

14

115. 13 (20.79)

113.19 (19.12)

0.71 (−0.02, 1.40)

 

PANSS

14

56.81 (10.86)

41.63 (10.33)

14

61.25 (15.58)

60.06 (13.94)

−1.46 (−2.31, −0.61)

Schulz et al. (2013) [20]

CDR

54

3.83 (6.80)

3.34 (5.36)

39

4.19 (5.79)

6.36 (10.56)

−0.38 (−0.79, 0.04)

 

DAI-30

69

22.46 (6.83)

22.70 (6.59)

46

22.70 (6.69)

22.83 (5.89)

−0.02 (−0.39, 0.35)

 

MARS

69

7.55 (2.07)

7.75 (2.01)

46

7.46 (1.73)

7.65 (1.87)

0.03 (−0.35, 0.40)

 

PANSS

63

48.32 (13.83)

44.13 (10.67)

42

49.33 (14.74)

50.29 (13.67)

−0.51 (−0.91, −0.11)

von Bormann et al. (2015)

DAI-30

38

15.74 (8.85)

20.11 (4.79)

32

15.91 (7.69)

18.91 (7.24)

0.20 (−0.27, 0.67)

 

PANSS

38

46.76 (16.06)

43.13 (13.92)

32

48.19 (16.05)

48.50 (15.42)

−0.36 (−0.84, 0.11)

  1. Abbreviations: ARS adherence rating scale [30], BPRS brief psychiatric rating scale [24], CDR concentration to dose ratio, DAI Hogan drug attitude inventory [27], ITAQ insight and treatment attitude questionnaire [29], MAQ medication adherence questionnaire [31], MARS medication adherence rating scale [32], PANSS positive and negative syndrome scale [23], PETiT personal evaluation of transitions in treatment scale [28], SAI-C schedule for assessment of insight – compliance item [25]